Reports Q4 revenue ($1.6M), consensus $4.19M. "The past year has been transformational for Voyager," said Alfred Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. "Since I became CEO of Voyager last March, we have re-prioritized our pipeline to focus on some of the most significant unmet needs in neurology, advanced our four lead programs towards the clinic, achieved breakthrough innovations in novel capsid discovery including the identification of a receptor, and entered multiple high-value partnerships. The strategic collaboration with Neurocrine that we announced in January illustrates the value of our next-generation gene therapies for CNS diseases, and this value is further evidenced by capsid license option exercises by Pfizer in October and recently by Novartis for multiple CNS targets. These partnerships strengthen our balance sheet and allow us to invest in our platform as well as existing and new neuro-genetic medicine programs."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VYGR:
- Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
- Voyager announces Novartis exercised option to license novel capsids for $25M
- Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
- Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
